Serko FY26 Interim Results
| Stock | Serko Ltd (SKO.ASX) |
|---|---|
| Release Time | 18 Nov 2025, 7:30 a.m. |
| Price Sensitive | Yes |
Serko delivers 45% total income growth and EBITAFI uplift
- Driven by GetThere and momentum in Booking.com for Business
- Completed room nights up 32% to 2.1 million, underpinned by growth in Active customers
- Active customers increased 40% compared to 1H25
Serko Limited (NZX & ASX: SKO) today reports its unaudited interim results for the six months to 30 September 2025 (1H26), with total income growth of 45% compared to 1H25 to $61.8 million, reflecting continued strong growth with cost discipline. EBITDAFI grew to $6.1 million. Momentum in Booking.com for Business drove Serko's result, with Completed Room Nights up 32% to 2.1 million, underpinned by growth in Active customers and new product capabilities delivered. Active customers increased 40% compared to 1H25. GetThere, acquired in January, drove a step change in Serko's US business. US revenue slightly exceeded expectations as expected customer exits occurred more slowly. Serko has stabilised its customer base, with new ARR churn on key accounts around 1% of annualised revenue. Australasian travel revenue was stable with Online Bookings up 2% and improved margins. A -2% decline in average revenue per booking was driven by reduced third-party pass-through costs. Serko made progress during the half year on increasing its strategic focus including exiting its US InterplX expense management business on 30 September 2025. Serko also continues to optimise its operating model to unlock the value of AI and emerging technologies.
Serko reaffirms its FY26 total income guidance of $115 million - $123 million. Serko has revised its Total Spend range to $124 million - $128 million for FY26, from $127 million - $133 million previously.
Serko is co-designing AI-powered capabilities with customers in the US and receiving positive customer and prospect engagement. Risks to Serko achieving its FY26 goals include macro economic and geopolitical factors, and currency and ARPCRN movements.